A new experimental diabetes jab, retatrutide, has shown promising Phase-3 trial results, helping type 2 diabetes patients lose up to 15% of body weight and significantly improve blood sugar control. The once-weekly injectable targets three hormone receptors, with the highest dose reducing HbA1c by 1.94 percentage points and body weight by 15.3%.
A new experimental diabetes jab, retatrutide, has shown promising Phase-3 trial results, helping type 2 diabetes patients lose up to 15% of body weight and significantly improve blood sugar control. The once-weekly injectable targets three hormone receptors, with the highest dose reducing HbA1c by 1.94 percentage points and body weight by 15.3%.
<iframe src="https://hindustansphere.com/embed/cluster/97b2345b1cd2f4912ee39925b5d29243445e3bb0" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="New diabetes jab cuts weight by 15%, improves sugar control in global trial"></iframe>
